OVERVIEW TUESDAY, NOVEMBER 9, 2021

9:00-10:30 am  
**Live Session I**
- **CAR T cells for cancer therapy**
  - **Keynote:** Rössig, Claudia (Münster University Hospital [UKM], Münster, Germany)
- **Cell based therapy in hematology**
  - **Keynote:** Ciceri, Fabio (IRCCS Ospedale San Raffaele, Milan, Italy)

10:30–11:00 am  
**Break**

11:00 am – 12:00 pm  
**Poster Session I – Improving the efficacy and safety profile of cell therapies**
- **Biomarkers and immuno monitoring**
  - Poster authors (group 1) are available for live chat.

12:00–12:30 pm  
**Break**

12:30-1:15 pm  
**Industry Sponsored Session**
- Supported by Gilead
- **DLBCL: CAR-T data and clinical experience**
  - Glaß, Bertram (Helios Clinic Berlin-Buch, Berlin, Germany)
- **CAR-T cell therapy in Germany: Clinical experience and status quo**
  - Vucinic, Vladan (University of Leipzig Medical Center, Leipzig, Germany)
- **MCL: CAR-T data and clinical experience**
  - Heß, Georg (University Medical Center Mainz, Mainz, Germany)

1:15-1:20 pm  
**Break**

1:20-1:45 pm  
**Industry Flash Talk - Novel immunotherapeutic approaches in multiple myeloma and solid tumors**
- Supported by GlaxoSmithKline
  - **Introduction and Belantamab mafodotin trials**
    - Merz, Maximilian (University of Leipzig Medical Center, Leipzig, Germany)
  - **Targeting NY-ESO-1 for personalized cancer immunotherapy**
    - Schmitt, Michael (Heidelberg University Hospital, Heidelberg, Germany)
  - **Discussion and closure**
    - Merz, Maximilian (University of Leipzig Medical Center, Leipzig, Germany)

1:45-2:15 pm  
**Break**

2:15-3:45 pm  
**Live Session II**
- **From CARs to TRUCKs: the 4th generation of CAR T cells**
  - **Keynote:** Abken, Hinrich (RCI – University of Regensburg, Regensburg, Germany)
  - **Beyond CD19 – CAR-T cells targeting solid tumors**
    - Cathomen, Toni (Medical Center – University of Freiburg, Freiburg, Germany)

3:45-4:15 pm  
**Break**

4:15-5:15 pm  
**Poster Session II – Cell-based therapy in oncology | Cell-based therapy in hematology | Cancer vaccines and vector-based therapy**
- Poster authors (group 2) are available for live chat.
OVERVIEW WEDNESDAY, NOVEMBER 10, 2021

9:00-10:30 am
Live Session III
Cellular therapy for the treatment of solid cancers
Keynote | Haanen, John (The Netherlands Cancer Institute, Amsterdam, The Netherlands)
Combining cell therapy and immune checkpoint inhibitors
Keynote | Chabannon, Christian (Institut Paoli-Calmettes, Marseille, France)

10:30-11:00 am
Break

11:00 am - 12:00 pm
Poster Session III – Tumor microenvironment | Precision medicine addressing tolerance and inflammation
Poster authors (group 3) are available for live chat.

12:00 – 12:30 pm
Break

12:30-1:15 pm
Industry Sponsered Session – 3 Immuno-Swords fighting cancer: Inhibition of Pro-Tumor inflammation, TIM-3-Inhibition and CAR-T-cells
Supported by Novartis

Pro-Tumor Inflammation (PTI) - a new target for fighting cancer. First findings in NSCLC.
Kobold, Sebastian (University Hospital of Munich (LMU), Munich, Germany)
Immune targeted approaches in myeloid neoplasms and lymphoma
Platzecker, Uwe (University of Leipzig Medical Center, Leipzig, Germany)

1:15-1:20 pm
Break

1:20-2:05 pm
Industry Sponsered Session – New therapy approaches in hematology and immunooncology
Supported by Bristol Myers Squibb

Bristol Myers Squibb

CAR-T-cell therapies for multiple myeloma
Kortüm, Martin (University Hospital Würzburg, Würzburg, Germany)
State of the art therapy – Immunooncology in 2021 – What is new?
Ivanyi, Philipp (MHH, Hannover, Germany)
Discussion of all speakers

2:05–2:15 pm
Break

2:15–3:45 pm
Live Session IV
Genomic biomarkers of immunotherapy response and monitoring
Keynote | Dienstmann, Rodrigo (Vall d'Hebron Institute of Oncology, Barcelona, Spain)
Precision medicine addressing tolerance and inflammation
Keynote | Kordasti, Shahram (Kings College London, London, UK)

3:45-4:15 pm
Break

4:15-5:00 pm
Industry Sponsered Session
Supported by Amgen

T cell engaging therapies: Blinatumomab and beyond
Bargou, Ralf C. (University Hospital Würzburg, Würzburg, Germany)
Klinger, Matthias (Amgen Research (Munich) GmbH, Munich, Germany)